Your browser doesn't support javascript.
loading
Micromolecular methods for diagnosis and therapeutic strategy: a case study.
Elbouchtaoui, Morad; Tengher, Iulia; Miquel, Catherine; Brugière, Charlotte; Benbara, Amélie; Zelek, Laurent; Ziol, Marianne; Bouhidel, Fatiha; Janin, Anne; Bousquet, Guilhem; Leboeuf, Christophe.
Afiliação
  • Elbouchtaoui M; Université Paris Diderot, Inserm, UMR_S1165, Paris, France.
  • Tengher I; Pathology Department, Hôpital St Louis, APHP, Paris, France.
  • Miquel C; Pathology Department, Hôpital Jean Verdier, APHP, Bondy, France.
  • Brugière C; Université Paris Diderot, Inserm, UMR_S1165, Paris, France.
  • Benbara A; Pathology Department, Hôpital St Louis, APHP, Paris, France.
  • Zelek L; Université Paris Diderot, Inserm, UMR_S1165, Paris, France.
  • Ziol M; Obstetrics and Gynecology Department, Hôpital Jean Verdier, APHP, Bondy, France.
  • Bouhidel F; Université Paris 13, Villetaneuse, France.
  • Janin A; Oncology Department, Hôpital Avicenne, APHP, Bobigny, France.
  • Bousquet G; Pathology Department, Hôpital Jean Verdier, APHP, Bondy, France.
  • Leboeuf C; Université Paris 13, Villetaneuse, France.
Oncotarget ; 9(32): 22862-22869, 2018 Apr 27.
Article em En | MEDLINE | ID: mdl-29854320
ABSTRACT
An intraductal carcinoma, 55 mm across, was diagnosed on a total mastectomy in a 45-year-old woman. The 2 micro-invasive areas found were too small for reliable immunostainings for estrogen, progesterone, and HER2 receptors. In the sentinel lymph-node, a subcapsular tumor embole of about 50 cancer cells was identified on the extemporaneous cryo-cut section, but not on further sections after paraffin-embedding of the sample. Considering this tumor metastatic potential, we decided to assess HER2 status on the metastatic embole using pathological and molecular micro-methods. We laser-microdissected the tumor cells, extracted their DNA, and performed droplet-digital-PCR (ddPCR) for HER2 gene copy number variation. The HER2/RNaseP allele ratio was 5.2 in the laser-microdissected tumor cells, similar to the 5.3 ratio in the HER2-overexpressing breast cancer cell line BT-474. We thus optimized the adjuvant treatment of our patient and she received a trastuzumab-based adjuvant chemotherapy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França